We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
DXS International plc | AQSE:DXSP | Aquis Stock Exchange | Ordinary Share | GB00B2Q6HZ92 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.35 | 1.00 | 2.20 | 1.60 | 1.35 | 1.35 | 0.00 | 16:29:58 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMDXSP DXS INTERNATIONAL PLC INTERIM RESULTS The Board of DXS International Plc ("DXS" or the "Company"), the ISDX quoted developer and supplier of clinical decision support systems to Clinical Commissioning Groups, GPs, doctors and healthcare professionals, is pleased to announce its Interim Results for the 6 months ended 31 October 2015. HIGHLIGHTS: -- Revenues increased by 31% to GBP1.52m (2014 GBP1.16m) -- Profit increased by GBP92,000 to GBP54,000 (2014 Loss GBP38,000) -- Earnings per share increased to 0.2p (2014 Loss 0.1p) per share -- Current run rate is GBP3.4m p.a. - an increase of 25% on year ending April 2015 -- DXS has now signed 37 CCGs The six months results reflect the team's efforts to produce positive results and has seen the Company extending its reach into the UK primary care market. We now have 37 CCG clients which is an increase of 8 from the same period in 2014. We have a strong forward looking pipeline as we continue with our program of aggressive sales and marketing to the sector, underpinned by a high quality of service delivery. The significant increase in staff and systems required to comply with the NHS conditions of GPSoc has now tapered off and the Board expects future cost increases will be required only for servicing increases in client numbers and new projects. The Company's trading is cashflow positive and comfortably within its facility limits. As the NHS continues to seek ways of curbing ever increasing costs - for example in 2017 it is estimated that an additional one million UK residents will fall into the 70+ age category - DXS is strategically positioned to capitalise on the emerging and innovative cost saving and care improvement initiatives within the UK. We look forward to reporting on our further progress in due course. David Immelman CEO INTERIM RESULTS TO 31(st) OCTOBER 2015 CONSOLIDATED PROFIT AND LOSS ACCOUNT for the six month period ended 31(st) October 2015 Restated Unaudited Group Unaudited Audited 6 Months ended 6 Months ended Year to 31st Oct 2015 31st Oct 2014 30th April 2015 GBP GBP GBP Turnover 1,521,081 1,164,476 2,723,762 Cost of Sales (222,008) (223,576) (461,608) _________ _________ _________ 1,299,073 940,900 2,262,154 Administrative Expenses (1,140,076) (782,643) (2,149,982) Goodwill written off nil nil Selling Expenses (155,350) (150,468) Provision for costs of share option scheme (27,000) (70,000) (108,580) _________ _________ _________ Operating Profit/(Loss) (23,353) (62,211) 3,592 Other interest receivable and similar income 1,184 1,073 2,170 Interest payable and similar charges (16,378) (16,812) (35,477) _________ _________ _________ Profit/(Loss) on Ordinary Activities before taxation (38,547) (77,950) (29,715) Taxation on ordinary activities 92,974 50,000 272,290 _________ _________ _________ Profit/ (Loss) for the period 54,427 (27,950) 242,575 ========= ========= ========= Profit/ (Loss) per share 0.2p (0.1)p 0.7p -- basic 0.1p (0.1)p 0.6p -- fully diluted ========= ========= ========= Notes: the 2015 figures have been adjusted for the effect of FRS 102 which will be applicable to the accounts for the year ending 30th April 2016, and for the grant of options to management which took place in the second half of 2015. The balance sheet has also been restated for these effects to allow for comparability. All amounts relate to continuing activities. All recognised gains and losses are included in the profit and loss account. . CONSOLIDATED BALANCE SHEET as at 31(st) October 2015 Restated Unaudited Unaudited Restated Group Group Audited Group 31st Oct 2015 31st Oct 201 30(th) April 2014 GBP GBP GBP Fixed Assets Intangible Assets 2,525,596 2,654,028 2,461,732 Tangible Assets 16,232 41,810 22,132 _________ _________ _________ 2,541,828 2,695838 2,483,864 _________ _________ _________ Current assets Debtors -- Amounts due in less than one year 1,307,737 606,007 1,068,112 -- Amounts due in more than one year 80,254 89,251 85,842 Cash at bank and in hand 307,671 397,767 480,928 _________ _________ _________ 1,695,662 1,093,025 1,634,882 Creditors: amounts falling due within one year (2,063,792) (1,468,275) (1,942,841) _________ _________ _________ Net current liabilities (368,130) (375,250) (307,959) _________ _________ _________ Total assets less current liabilities 2,173,698 2,320,588 2,175,905 Creditors: amounts falling due after more than one year (158,494) (332,526) (242,128) _________ _________ _________ 2,015,204 1,988,062 1,933,777 ========= ========= ========= Capital and reserves Called up share capital 108,592 108,518 108,592 Share Premium account 1,591,709 1,584,047 1,591,709 Provision for costs of share option awards 135,580 70,000 108,580 Profit and loss account 179,323 225,497 124,896 _________ _________ _________ 2,015,204 1,988,062 1,933,777 ========= ========= ========= The above figures have not been reviewed by the company's auditors LDP Luckmans. The Directors of DXS International plc accept responsibility for this announcement Contacts: David Immelman, CE0 01252 719800 DXS International Plc www.dxs-systems.com Corporate Adviser City & Merchant Ltd David Papworth 020 7101 7676 MB Communications Maxine Barnes 07860489571 Notes to Editors About DXS: DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings. This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: DXS International plc via Globenewswire HUG#1883743 http://www.dxs-systems.com/
(END) Dow Jones Newswires
February 01, 2016 02:30 ET (07:30 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year DXS Chart |
1 Month DXS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions